7 research outputs found
Impact of the surgical strategy on the incidence of C5 nerve root palsy in decompressive cervical surgery - Fig 2
<p>Sagittal schematic of the surgical spine to illustrate C5 palsy rate of two level hybrid constructs, i.e. combination of corpectomy and ACDF, for the levels C4-7 (A) and C3-6 (B). Statistical values are summarized in C, including overall C5 incidence rate for hybrid constructs on all levels around the vulnerable level of C4/C5. Additional information on other possible surgical constructs around the level of C4/C5 is presented in D, allowing for the direct comparison of C5 palsy rate of the different surgical strategies. Statistical analysis applied routine cross tables and chi<sup>2</sup> testing.</p
Edema is not a reliable diagnostic sign to exclude small brain metastases
<div><p>No prior systematic study on the extent of vasogenic edema (VE) in patients with brain metastases (BM) exists. Here, we aim to determine 1) the general volumetric relationship between BM and VE, 2) a threshold diameter above which a BM shows VE, and 3) the influence of the primary tumor and location of the BM in order to improve diagnostic processes and understanding of edema formation. This single center, retrospective study includes 173 untreated patients with histologically proven BM. Semi-manual segmentation of 1416 BM on contrast-enhanced T1-weighted images and of 865 VE on fluid-attenuated inversion recovery/T2-weighted images was conducted. Statistical analyses were performed using a paired-samples t-test, linear regression/generalized mixed-effects model, and receiver-operating characteristic (ROC) curve controlling for the possible effect of non-uniformly distributed metastases among patients. For BM with non-confluent edema (n = 545), there was a statistically significant positive correlation between the volumes of the BM and the VE (P < 0.001). The optimal threshold for edema formation was a diameter of 9.4 mm for all BM. The primary tumors as interaction term in multivariate analysis had a significant influence on VE formation whereas location had not. Hence VE development is dependent on the volume of the underlying BM and the site of the primary neoplasm, but not from the location of the BM.</p></div
Overview of thresholds for BM formation of all patients and the different primary tumors.
<p>Overview of thresholds for BM formation of all patients and the different primary tumors.</p
ROC curve determining the best threshold (maximum sensitivity and maximum specifity) for development of vasogenic edema of all BM in the study (red star = 0.48 ml).
<p>The red line represents the empirical ROC curve, the light red area shows the 95% confidence interval, and the blue line is a smoother of the empiric ROC curve. Sensitivity, specifity, positive predictive value (ppv), negative predictive value (npv), and area under the curve are also given.</p
Distribution and size of BM and VE among the whole cohort and the different primary tumors.
<p>Distribution and size of BM and VE among the whole cohort and the different primary tumors.</p
Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models
Rhizochalinin (Rhiz) is a recently
discovered cytotoxic
sphingolipid
synthesized from the marine natural compound rhizochalin. Previously,
Rhiz demonstrated high in vitro and in vivo efficacy in various cancer
models. Here, we report Rhiz to be highly active in human glioblastoma
cell lines as well as in patient-derived glioma-stem like neurosphere
models. Rhiz counteracted glioblastoma cell proliferation by inducing
apoptosis, G2/M-phase cell cycle arrest, and inhibition of autophagy.
Proteomic profiling followed by bioinformatic analysis suggested suppression
of the Akt pathway as one of the major biological effects of Rhiz.
Suppression of Akt as well as IGF-1R and MEK1/2 kinase was confirmed
in Rhiz-treated GBM cells. In addition, Rhiz pretreatment resulted
in a more pronounced inhibitory effect of γ-irradiation on the
growth of patient-derived glioma-spheres, an effect to which the Akt
inhibition may also contribute decisively. In contrast, EGFR upregulation,
observed in all GBM neurospheres under Rhiz treatment, was postulated
to be a possible sign of incipient resistance. In line with this,
combinational therapy with EGFR-targeted tyrosine kinase inhibitors
synergistically increased the efficacy of Rhiz resulting in dramatic
inhibition of GBM cell viability as well as a significant reduction
of neurosphere size in the case of combination with lapatinib. Preliminary
in vitro data generated using a parallel artificial membrane permeability
(PAMPA) assay suggested that Rhiz cannot cross the blood brain barrier
and therefore alternative drug delivery methods should be used in
the further in vivo studies. In conclusion, Rhiz is a promising new
candidate for the treatment of human glioblastoma, which should be
further developed in combination with EGFR inhibitors
Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models
Rhizochalinin (Rhiz) is a recently
discovered cytotoxic
sphingolipid
synthesized from the marine natural compound rhizochalin. Previously,
Rhiz demonstrated high in vitro and in vivo efficacy in various cancer
models. Here, we report Rhiz to be highly active in human glioblastoma
cell lines as well as in patient-derived glioma-stem like neurosphere
models. Rhiz counteracted glioblastoma cell proliferation by inducing
apoptosis, G2/M-phase cell cycle arrest, and inhibition of autophagy.
Proteomic profiling followed by bioinformatic analysis suggested suppression
of the Akt pathway as one of the major biological effects of Rhiz.
Suppression of Akt as well as IGF-1R and MEK1/2 kinase was confirmed
in Rhiz-treated GBM cells. In addition, Rhiz pretreatment resulted
in a more pronounced inhibitory effect of γ-irradiation on the
growth of patient-derived glioma-spheres, an effect to which the Akt
inhibition may also contribute decisively. In contrast, EGFR upregulation,
observed in all GBM neurospheres under Rhiz treatment, was postulated
to be a possible sign of incipient resistance. In line with this,
combinational therapy with EGFR-targeted tyrosine kinase inhibitors
synergistically increased the efficacy of Rhiz resulting in dramatic
inhibition of GBM cell viability as well as a significant reduction
of neurosphere size in the case of combination with lapatinib. Preliminary
in vitro data generated using a parallel artificial membrane permeability
(PAMPA) assay suggested that Rhiz cannot cross the blood brain barrier
and therefore alternative drug delivery methods should be used in
the further in vivo studies. In conclusion, Rhiz is a promising new
candidate for the treatment of human glioblastoma, which should be
further developed in combination with EGFR inhibitors